Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandatory Part D Drug Rebates Proposed By Deficit Panel Leaders; Stronger IPAB Also On The Table

This article was originally published in The Pink Sheet Daily

Executive Summary

The co-chairs of the bipartisan National Commission on Fiscal Responsibility and Reform issued a cost-savings proposal for the government, including Medicare, on Nov. 10, but it will need approval by 14 of 18 members before going to the president.

You may also be interested in...



Obama Pitches Part D Rx Price Concessions In State Of The Union Address

President Obama’s speech includes some proposals for cost-savings in Medicare, such as having wealthier seniors pay more, moving from pay-for-service to pay-for-performance and mandatory rebates on drugs used in Medicare Part D, which drew a quick response from PhRMA.

Part D Mandatory Rebates Included In Speaker Boehner’s “Fiscal Cliff” Offer

House Speaker John Boehner made an offer to President Obama Dec. 3 to base a resolution to the looming fiscal cliff on a proposal by the president’s deficit commission headed by Erskine Bowles and Alan Simpson, a proposal that included a mandatory rebate on drugs used in Medicare Part D.

Fiscal Commission's Final Plan Includes Rebates On Drugs Used By Medicare/Medicaid Dual Eligibles

Commission will vote Dec. 3 on whether to approve the plan on ways to reduce federal deficits.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel